Related references
Note: Only part of the references are listed.The role of bortezomib in the treatment of lymphoma
Paul Barr et al.
CANCER INVESTIGATION (2007)
The spectrum of mutations in the PUT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption
Rongbao Zhao et al.
BLOOD (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma
Michelle A. Fanale et al.
DRUGS (2007)
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang et al.
BLOOD (2006)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly
AK Gandhi et al.
LEUKEMIA RESEARCH (2006)
Current treatment approaches for mantle-cell lymphoma
TE Witzig
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
FJ Hernandez-Ilizaliturri et al.
CLINICAL CANCER RESEARCH (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
S Lentzsch et al.
LEUKEMIA (2003)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
